Eads & Heald Wealth Management Sells 467 Shares of Danaher Co. (NYSE:DHR)

Eads & Heald Wealth Management lowered its position in Danaher Co. (NYSE:DHR) by 5.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 7,918 shares of the conglomerate’s stock after selling 467 shares during the quarter. Eads & Heald Wealth Management’s holdings in Danaher were worth $2,201,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of DHR. Vanguard Group Inc. boosted its stake in Danaher by 7.4% during the first quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock worth $15,009,928,000 after buying an additional 4,163,657 shares in the last quarter. Swedbank AB acquired a new stake in shares of Danaher during the 1st quarter valued at about $676,545,000. TD Asset Management Inc increased its stake in Danaher by 99.0% in the second quarter. TD Asset Management Inc now owns 1,358,706 shares of the conglomerate’s stock valued at $339,473,000 after acquiring an additional 675,952 shares during the period. Massachusetts Financial Services Co. MA lifted its stake in Danaher by 22.7% during the second quarter. Massachusetts Financial Services Co. MA now owns 3,047,728 shares of the conglomerate’s stock worth $761,475,000 after purchasing an additional 563,546 shares during the period. Finally, International Assets Investment Management LLC boosted its stake in Danaher by 40,196.5% in the 3rd quarter. International Assets Investment Management LLC now owns 429,964 shares of the conglomerate’s stock valued at $119,539,000 after buying an additional 428,897 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Trading Up 0.9 %

NYSE DHR opened at $247.82 on Friday. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. Danaher Co. has a 12 month low of $190.95 and a 12 month high of $281.70. The company has a market capitalization of $178.99 billion, a PE ratio of 47.29, a P/E/G ratio of 4.45 and a beta of 0.83. The stock has a 50-day simple moving average of $266.95 and a 200 day simple moving average of $260.37.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The business had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same quarter last year, the firm earned $2.02 EPS. Danaher’s quarterly revenue was up 3.1% compared to the same quarter last year. Research analysts forecast that Danaher Co. will post 7.51 EPS for the current year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were given a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. The ex-dividend date of this dividend was Friday, September 27th. Danaher’s dividend payout ratio is currently 20.61%.

Insider Buying and Selling

In other Danaher news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 11.10% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms have issued reports on DHR. Stifel Nicolaus increased their price objective on Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research note on Wednesday, October 23rd. Leerink Partners raised their price objective on shares of Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a report on Wednesday, July 24th. KeyCorp boosted their target price on Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a report on Wednesday, October 23rd. Wolfe Research raised Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price target for the company in a report on Thursday. Finally, UBS Group reduced their price objective on Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a research note on Wednesday, October 23rd. Six analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $287.16.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.